- Home
- CGNT vs MNPR Comparison
CGNT vs MNPR Comparison
Compare CGNT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | MNPR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.9M | 587.4M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CGNT | MNPR |
|---|---|---|
| Price | $8.49 | $113.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $13.50 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 478.7K | 251.4K |
| Earning Date | 06-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $32.77 |
| 52 Week High | $12.31 | $124.82 |
Technical Indicators
Market Signals| Indicator | CGNT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 50.08 |
| Support Level | $7.87 | $102.88 |
| Resistance Level | $9.38 | $114.60 |
| Average True Range (ATR) | 0.30 | 6.59 |
| MACD | -0.09 | -1.68 |
| Stochastic Oscillator | 9.32 | 30.79 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.